143 related articles for article (PubMed ID: 27470189)
1. Histone deacetylase inhibitors stimulate the susceptibility of A549 cells to a plasma-activated medium treatment.
Adachi T; Kano A; Nonomura S; Kamiya T; Hara H
Arch Biochem Biophys; 2016 Sep; 606():120-7. PubMed ID: 27470189
[TBL] [Abstract][Full Text] [Related]
2. Iron stimulates plasma-activated medium-induced A549 cell injury.
Adachi T; Nonomura S; Horiba M; Hirayama T; Kamiya T; Nagasawa H; Hara H
Sci Rep; 2016 Feb; 6():20928. PubMed ID: 26865334
[TBL] [Abstract][Full Text] [Related]
3. Ability of plasma-activated acetated Ringer's solution to induce A549 cell injury is enhanced by a pre-treatment with histone deacetylase inhibitors.
Adachi T; Matsuda Y; Ishii R; Kamiya T; Hara H
J Clin Biochem Nutr; 2020 Nov; 67(3):232-239. PubMed ID: 33293763
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
5. Sensitization to gamma-irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells.
Zhang F; Zhang T; Teng ZH; Zhang R; Wang JB; Mei QB
Cancer Biol Ther; 2009 May; 8(9):823-31. PubMed ID: 19270532
[TBL] [Abstract][Full Text] [Related]
6. Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance.
Krumm A; Barckhausen C; Kücük P; Tomaszowski KH; Loquai C; Fahrer J; Krämer OH; Kaina B; Roos WP
Cancer Res; 2016 May; 76(10):3067-77. PubMed ID: 26980768
[TBL] [Abstract][Full Text] [Related]
7. Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP.
Chao OS; Goodman OB
Mol Cancer Res; 2014 Dec; 12(12):1755-66. PubMed ID: 25127709
[TBL] [Abstract][Full Text] [Related]
8. New aryldithiolethione derivatives as potent histone deacetylase inhibitors.
Tazzari V; Cappelletti G; Casagrande M; Perrino E; Renzi L; Del Soldato P; Sparatore A
Bioorg Med Chem; 2010 Jun; 18(12):4187-94. PubMed ID: 20576572
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis.
Chung YL; Lee MY; Pui NN
Carcinogenesis; 2009 Aug; 30(8):1387-97. PubMed ID: 19351790
[TBL] [Abstract][Full Text] [Related]
10. Class I histone deacetylase inhibitors inhibit the retention of BRCA1 and 53BP1 at the site of DNA damage.
Fukuda T; Wu W; Okada M; Maeda I; Kojima Y; Hayami R; Miyoshi Y; Tsugawa K; Ohta T
Cancer Sci; 2015 Aug; 106(8):1050-6. PubMed ID: 26053117
[TBL] [Abstract][Full Text] [Related]
11. HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination.
Adimoolam S; Sirisawad M; Chen J; Thiemann P; Ford JM; Buggy JJ
Proc Natl Acad Sci U S A; 2007 Dec; 104(49):19482-7. PubMed ID: 18042714
[TBL] [Abstract][Full Text] [Related]
12. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
13. [Molecular Mechanisms Underlying Cellular Responses to the Loading of Non-thermal Atmospheric Pressure Plasma-activated Solutions].
Adachi T
Yakugaku Zasshi; 2021; 141(10):1185-1194. PubMed ID: 34602515
[TBL] [Abstract][Full Text] [Related]
14. Valproic acid, a histone deacetylase inhibitor, enhances radiosensitivity in esophageal squamous cell carcinoma.
Shoji M; Ninomiya I; Makino I; Kinoshita J; Nakamura K; Oyama K; Nakagawara H; Fujita H; Tajima H; Takamura H; Kitagawa H; Fushida S; Harada S; Fujimura T; Ohta T
Int J Oncol; 2012 Jun; 40(6):2140-6. PubMed ID: 22469995
[TBL] [Abstract][Full Text] [Related]
15. Targeting histones for degradation in cancer cells as a novel strategy in cancer treatment.
Yin Y; Zhu Q; Jiang T; Fan L; Qiu X
Sci China Life Sci; 2019 Aug; 62(8):1078-1086. PubMed ID: 30465232
[TBL] [Abstract][Full Text] [Related]
16. Induction of apoptosis by trichostatin A, a histone deacetylase inhibitor, is associated with inhibition of cyclooxygenase-2 activity in human non-small cell lung cancer cells.
Choi YH
Int J Oncol; 2005 Aug; 27(2):473-9. PubMed ID: 16010430
[TBL] [Abstract][Full Text] [Related]
17. Targeting histone deacetylase 4/ubiquitin-conjugating enzyme 9 impairs DNA repair for radiosensitization of hepatocellular carcinoma cells in mice.
Tsai CL; Liu WL; Hsu FM; Yang PS; Yen RF; Tzen KY; Cheng AL; Chen PJ; Cheng JC
Hepatology; 2018 Feb; 67(2):586-599. PubMed ID: 28646552
[TBL] [Abstract][Full Text] [Related]
18. Copper oxide nanoparticles induce anticancer activity in A549 lung cancer cells by inhibition of histone deacetylase.
Kalaiarasi A; Sankar R; Anusha C; Saravanan K; Aarthy K; Karthic S; Mathuram TL; Ravikumar V
Biotechnol Lett; 2018 Feb; 40(2):249-256. PubMed ID: 29116558
[TBL] [Abstract][Full Text] [Related]
19. HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia.
Lai TH; Ewald B; Zecevic A; Liu C; Sulda M; Papaioannou D; Garzon R; Blachly JS; Plunkett W; Sampath D
Clin Cancer Res; 2016 Jul; 22(14):3537-49. PubMed ID: 26858310
[TBL] [Abstract][Full Text] [Related]
20. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
